Lekha Mikkilineni: Studying Stem Cell Mobilization in the CD38-mAb Era
Lekha Mikkilineni, Assistant Professor in the BMT Division at Stanford University School of Medicine, shared a post on X about a paper published on Transplantation and Cellular Therapy:
“We studied stem cell mobilization in the CD38-mAb era.
In NDMM patients undergoing ASCT, CD38-mAb induction led to:
- Decreased yields (−9.4%)
- Increased plerixafor and apheresis
- +$23K mobilization costs Longer washout improved yields.”
Title: The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024
Authors: Dilek Uzun, Jeddeo Michael Paul, Alexandria Jensen, John Tamaresis, Walter Domingo, Sally Arai, Felipe Araya Ventura, Jennifer Rocha, Leslie Bennett, Amelia Jones, Sushma Bharadwaj, Laura Johnston, Robert Lowsky, Andrew Rezvani, Parveen Shiraz, Judith Shizuru, Wen-Kai Weng, Hitomi Hosoya, Surbhi Sidana, David Miklos, Lori Muffly, Lekha Mikkilineni
Read the full article.
More posts featuring Lekha Mikkilineni on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023